PROF Profound Medical Corp.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1628808 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY65.3%
TTM net income YoY17.4%
TTM EPS YoY295.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin73.9%
Operating margin-145.1%
Net margin-137.5%
FCF margin—
EBITDA margin-143.4%
Returns
ROE-87.0%
ROA-64.7%
ROIC (approx.)-157.1%
Asset turnover0.47x
Leverage & solvency
Liabilities / assets26.9%
Debt / equity0.21x
Current ratio4.54x
Interest coverage-105.79x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $16.10M | $10.68M | $7.20M | $6.68M | $6.87M |
| Cost of revenue | $4.71M | $3.64M | $2.89M | $3.66M | $3.92M |
| Gross profit | $11.39M | $7.04M | $4.31M | $3.02M | $2.95M |
| R&D expense | $20.60M | $16.96M | $14.42M | $14.69M | $15.28M |
| SG&A expense | $32.05M | $23.13M | $18.54M | $9.46M | $10.31M |
| Operating income | -$41.25M | -$33.06M | -$28.65M | -$32.13M | -$30.29M |
| Interest expense | $394,000 | $600,000 | $146,000 | $290,000 | $448,000 |
| Pretax income | -$42.32M | -$27.82M | -$28.45M | -$28.38M | -$30.59M |
| Income tax | $252,000 | -$2,000 | -$128,000 | $287,000 | $105,000 |
| Net income | -$42.57M | -$27.82M | -$28.32M | -$28.67M | -$30.70M |
| EBITDA | -$40.88M | -$32.35M | -$27.92M | -$30.52M | -$28.41M |
| EPS (basic) | 1.41 | 1.12 | 1.34 | 1.38 | 1.50 |
| EPS (diluted) | 1.41 | 1.12 | 1.34 | 1.38 | 1.50 |
| Weighted avg. shares (diluted) | 30.23M | 24.77M | 21.18M | — | — |
| Banking | |||||
| Net interest income | — | — | $1.64M | $803,000 | $205,000 |
| Balance sheet | |||||
| Cash & equivalents | $59.72M | $54.91M | $26.21M | $46.52M | $67.15M |
| Receivables | — | — | $7.29M | $6.34M | $1.41M |
| Inventory | $8.24M | $5.80M | $6.99M | $7.94M | $7.41M |
| Current assets | $76.09M | $69.06M | $41.90M | $62.02M | $77.12M |
| PP&E, net | $698,000 | $425,000 | $909,000 | $899,000 | $788,000 |
| Goodwill | — | — | — | — | $2.69M |
| Intangibles | $138,000 | $261,000 | $490,000 | $680,000 | $1.44M |
| Total assets | $77.47M | $70.23M | $43.96M | $64.42M | $86.78M |
| Current liabilities | $6.08M | $6.57M | $6.37M | $4.18M | $4.16M |
| Short-term debt | — | $1.74M | $2.10M | $523,000 | — |
| Long-term debt | $4.50M | $4.66M | $7.10M | $7.17M | — |
| Total debt | $4.50M | $6.40M | $9.21M | $7.70M | — |
| Total liabilities | $11.04M | $9.81M | $12.73M | $12.42M | $6.16M |
| Shareholders' equity | $66.43M | $60.42M | $31.22M | $52.60M | $80.62M |
| Net debt | -$55.22M | -$48.51M | -$17.00M | -$38.82M | — |
| Shares outstanding | 36.29M | 30.04M | 21.37M | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$38.21M | -$23.45M | -$22.61M | -$25.80M | -$22.36M |
| Capital expenditure | $176,000 | — | — | — | $32,000 |
| Free cash flow | -$38.38M | — | — | — | -$22.39M |
| Investing cash flow | -$242,000 | — | — | — | -$593,000 |
| Financing cash flow | $41.14M | $54.70M | $1.76M | $7.03M | $5.95M |
| Depreciation & amortization | $373,000 | $707,000 | $727,000 | $1.60M | $1.88M |
| Stock-based compensation | $5.49M | $2.58M | $3.42M | $4.24M | $7.21M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.